Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic impact of eligibility for adjuvant immunotherapy in locally advanced urothelial cancer

Published:2021-10-08 Issue: Volume: Page:
ISSN:2688-4526
Container-title:BJUI Compass
language:en
Short-container-title:BJUI Compass

Author:

Miura Yuki¹,Hatakeyama Shingo¹^ORCID,Tanaka Toshikazu²,Fujita Naoki¹,Horiguchi Hirotaka¹,Okuyama Yoshiharu¹,Kojima Yuta¹,Noro Daisuke³,Tokui Noriko⁴,Okamoto Teppei¹,Yamamoto Hayato¹,Ito Hiroyuki⁵,Yoneyama Takahiro⁶,Hashimoto Yasuhiro¹,Ohyama Chikara¹⁶

Affiliation:

1. Department of Urology Hirosaki University Graduate School of Medicine Hirosaki Japan

2. Department of Urology Aomori Prefectural Central Hospital Aomori Japan

3. Department of Urology Mutsu General Hospital Mutsu Japan

4. Department of Urology Odate Municipal Hospital Odate Japan

5. Department of Urology Aomori Rosai Hospital Hachinohe Japan

6. Department of Advanced Transplant and Regenerative Medicine Hirosaki University Graduate School of Medicine Hirosaki Japan

Funder

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Religious studies,Cultural Studies

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/bco2.117

Reference29 articles.

1. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update;Rouprêt M;Eur Urol,2021

2. European Association of Urology guidelines on muscle‐invasive and metastatic bladder cancer: summary of the 2020 guidelines;Witjes JA;Eur Urol,2021

3. Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision;Matsumoto H;Int J Urol,2020

4. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman HB;N Engl J Med,2003

5. Neoadjuvant chemotherapy for muscle‐invasive bladder cancer: a systematic review and two‐step meta‐analysis;Yin M;Oncologist,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine‐based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle‐invasive bladder cancer cases—Single‐center study in Japan;International Journal of Urology;2024-05-31

2. Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy;Japanese Journal of Clinical Oncology;2023-11-15

3. Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study;International Journal of Clinical Oncology;2023-10-21

4. Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study;Japanese Journal of Clinical Oncology;2022-12-08

5. Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial;Japanese Journal of Clinical Oncology;2022-10-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3